Cabaletta Bio Management
Management criteria checks 2/4
Cabaletta Bio's CEO is Steven Nichtberger, appointed in Jan 2017, has a tenure of 7.83 years. total yearly compensation is $4.81M, comprised of 12.4% salary and 87.6% bonuses, including company stock and options. directly owns 2.76% of the company’s shares, worth $2.52M. The average tenure of the management team and the board of directors is 3 years and 4.8 years respectively.
Key information
Steven Nichtberger
Chief executive officer
US$4.8m
Total compensation
| CEO salary percentage | 12.4% |
| CEO tenure | 7.8yrs |
| CEO ownership | 2.8% |
| Management average tenure | 3yrs |
| Board average tenure | 4.8yrs |
Recent management updates
Recent updates
Cabaletta: Biotech With Large Potential, Interesting Bottom Pattern, Plenty Of Cash
Oct 22We're Hopeful That Cabaletta Bio (NASDAQ:CABA) Will Use Its Cash Wisely
Sep 04
Cabaletta Bio: Next Data Readout Needs To Be Mic Drop Moment
Jun 28Cabaletta Bio (NASDAQ:CABA) Is In A Good Position To Deliver On Growth Plans
May 22Cabaletta Bio: Two Differentiated CAR-T Platforms To Carry It Forward
Jan 31Cabaletta Bio (NASDAQ:CABA) Is In A Good Position To Deliver On Growth Plans
Dec 28Here's Why We're Not Too Worried About Cabaletta Bio's (NASDAQ:CABA) Cash Burn Situation
Sep 12Here's Why We're Not Too Worried About Cabaletta Bio's (NASDAQ:CABA) Cash Burn Situation
Jun 04Cabaletta Bio (NASDAQ:CABA) Is In A Good Position To Deliver On Growth Plans
Feb 11We Think Cabaletta Bio (NASDAQ:CABA) Needs To Drive Business Growth Carefully
Oct 20We Think Cabaletta Bio (NASDAQ:CABA) Needs To Drive Business Growth Carefully
Jul 07Cabaletta Bio (NASDAQ:CABA) Is In A Good Position To Deliver On Growth Plans
Mar 24We're Hopeful That Cabaletta Bio (NASDAQ:CABA) Will Use Its Cash Wisely
Dec 09We're Not Very Worried About Cabaletta Bio's (NASDAQ:CABA) Cash Burn Rate
Aug 05Cabaletta Bio EPS beats by $0.08
May 03Cabaletta Bio (NASDAQ:CABA) Is In A Good Position To Deliver On Growth Plans
Apr 12What Percentage Of Cabaletta Bio, Inc. (NASDAQ:CABA) Shares Do Insiders Own?
Feb 19
Chardan Capital initiates Cabaletta Bio with Buy rating
Jan 08We're Hopeful That Cabaletta Bio (NASDAQ:CABA) Will Use Its Cash Wisely
Dec 28Dosing underway in Cabaletta Bio's DSG3-CAART study in a rare skin blistering disorder
Dec 09Cabaletta Bio +5% on Q3 results, pipeline update
Nov 10CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$104m |
| Jun 30 2024 | n/a | n/a | -US$90m |
| Mar 31 2024 | n/a | n/a | -US$77m |
| Dec 31 2023 | US$5m | US$597k | -US$68m |
| Sep 30 2023 | n/a | n/a | -US$62m |
| Jun 30 2023 | n/a | n/a | -US$57m |
| Mar 31 2023 | n/a | n/a | -US$56m |
| Dec 31 2022 | US$2m | US$569k | -US$53m |
| Sep 30 2022 | n/a | n/a | -US$51m |
| Jun 30 2022 | n/a | n/a | -US$51m |
| Mar 31 2022 | n/a | n/a | -US$50m |
| Dec 31 2021 | US$4m | US$542k | -US$46m |
| Sep 30 2021 | n/a | n/a | -US$42m |
| Jun 30 2021 | n/a | n/a | -US$39m |
| Mar 31 2021 | n/a | n/a | -US$36m |
| Dec 31 2020 | US$4m | US$516k | -US$33m |
| Sep 30 2020 | n/a | n/a | -US$29m |
| Jun 30 2020 | n/a | n/a | -US$26m |
| Mar 31 2020 | n/a | n/a | -US$21m |
| Dec 31 2019 | US$1m | US$437k | -US$22m |
| Sep 30 2019 | n/a | n/a | -US$19m |
| Jun 30 2019 | n/a | n/a | -US$23m |
| Mar 31 2019 | n/a | n/a | -US$21m |
| Dec 31 2018 | US$1m | US$213k | -US$12m |
Compensation vs Market: Steven's total compensation ($USD4.81M) is above average for companies of similar size in the US market ($USD652.28K).
Compensation vs Earnings: Steven's compensation has increased whilst the company is unprofitable.
CEO
Steven Nichtberger (63 yo)
7.8yrs
Tenure
US$4,808,279
Compensation
Dr. Steven A. Nichtberger, M.D., serves as managing partner of GBF Advisors, LLC. Dr. Nichtberger is an adjunct professor at The Wharton School at the University of Pennsylvania. He is Co-Founder of Cabale...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 7.8yrs | US$4.81m | 2.76% $ 2.5m | |
| Chief Medical Officer | 5.4yrs | US$2.10m | 0% $ 0 | |
| President of Science & Technology | no data | US$2.34m | 0.041% $ 37.4k | |
| Co-Founder & Co-Chair of Scientific Advisory Board | no data | no data | no data | |
| Co-Founder & Co-Chair of Scientific Advisory Board | no data | no data | no data | |
| Chief Financial Officer | 5.8yrs | US$1.53m | no data | |
| Chief Technology Officer | less than a year | no data | no data | |
| Chief Scientific Officer | 3yrs | no data | no data | |
| General Counsel & Secretary | 3.2yrs | no data | no data | |
| Chief Compliance Officer | 3yrs | no data | no data | |
| Chief Human Resources Officer | no data | no data | no data | |
| Chief Business Officer | 2.8yrs | no data | no data |
3.0yrs
Average Tenure
51yo
Average Age
Experienced Management: CABA's management team is considered experienced (3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 7.8yrs | US$4.81m | 2.76% $ 2.5m | |
| Co-Founder & Co-Chair of Scientific Advisory Board | no data | no data | no data | |
| Co-Founder & Co-Chair of Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 5.8yrs | US$259.20k | 0% $ 0 | |
| Member of Scientific Advisory Board | 4.3yrs | no data | no data | |
| Independent Director | 6.1yrs | US$260.15k | 0.29% $ 267.7k | |
| Member of Scientific Advisory Board | 3.4yrs | US$202.24k | no data | |
| Independent Director | 3.4yrs | US$255.83k | 0% $ 0 | |
| Member of Scientific Advisory Board | 4.8yrs | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | 2.9yrs | no data | no data | |
| Independent Director | 5.6yrs | US$255.43k | 0.0021% $ 1.9k |
4.8yrs
Average Tenure
63yo
Average Age
Experienced Board: CABA's board of directors are considered experienced (4.8 years average tenure).